Treatment with Aclasta resulted in an increase in BMD of 5.4% at the total hip and 4.3% at the femoral neck over 24 months as compared to placebo.
24 mėnesių gydymas Aclasta, palyginti su gydymu placebu, bendrą šlaunikaulio KMT padidino 5, 4%, šlaunikaulio kaklo KMT – 4, 3%.